Regeneron Pharmaceuticals, Inc. Grabs EU Approval for New Use of EYLEA

EYLEAA Injection Approved in Europe for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion TARRYTOWN, N.Y. /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. today announced that EYLEAA Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema ... (more)

http://www.biospace.com/news_story.aspx?StoryID=307092&full=1